Compare ORBS & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORBS | XFOR |
|---|---|---|
| Founded | 1966 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.0M | 288.5M |
| IPO Year | 2022 | 2017 |
| Metric | ORBS | XFOR |
|---|---|---|
| Price | $0.76 | $3.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.60 |
| AVG Volume (30 Days) | ★ 14.9M | 761.6K |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,820,779.00 | $6,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 150.00 |
| 52 Week Low | $0.57 | $2.43 |
| 52 Week High | $7.17 | $4.83 |
| Indicator | ORBS | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 37.63 | 56.44 |
| Support Level | $0.74 | $3.19 |
| Resistance Level | $0.92 | $4.49 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 17.09 | 93.55 |
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business. Corrugated Packaging Business manufactured and sold custom packaging for a wide products and through packaging helps customers generate brand awareness and promote brand image. Generate the substantial majority of revenues from inventory financing and inventory management services.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.